Nycomed Amersham submits Sonazoid in Europe:
This article was originally published in Clinica
Executive Summary
UK company Nycomed Amersham has submitted Sonazoid, its ultrasound contrast agent for cardiology and radiology applications to the European Medicines Evaluation Agency for approval. The agent has already been submitted to the US FDA and the company is also investigating the use of Sonazoid in myocardial perfusion imaging.
You may also be interested in...
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.
Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel
Cerevel, which AbbVie is spending $8.7bn to acquire, unveiled topline results from the TEMPO-3 study of tavapadon, which an analyst said represents potentially a $1bn opportunity.
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.